Nightingale wins Finnish Startup of the Year Award
Sep 27, 2018
"The winning startup is on an important mission, solving the global burden of chronic diseases. The proven company shows you can do a lot in a short time in MedTech. They impressed the jury with real performance over the last year." - Nordic Startup Awards Jury
Nightingale has been selected as Startup of the Year at the Finnish Finale of the Nordic Startup Awards 2018. The award is given to "a tech startup that has shown the greatest development over the last year based on growth, innovation, and impact with a product or service.” Nightingale was also chosen as the Best Health-Tech Startup at the event organized by Helsinki Think Company.
As a national winner, Nightingale will compete with other winners from Sweden, Denmark, Norway and Iceland at the Nordic Startup Awards Finale in October. The regional winners will then compete at the Global Startup Awards in China.
“It’s an honour to be recognised by the Nordic Startup Awards and to represent Finland in the Nordic Finals in Copenhagen. The past three years have been amazing for Nightingale. We’re in a position where we not only have a great product but also have a fantastic team,” said Nightingale CEO and Founder Teemu Suna.
The Nordic Startup Awards is part of the Global Startup Awards, the biggest independent startup ecosystem competition with a mission to find, recognize and connect the futureshapers of the digital age from all around the world. Starting in the Nordics in 2012, the Global Startup Awards brings together amazing ideas and best talents from 5 regions and 40+ countries across the globe to celebrate entrepreneurial spirit and startups.
Nightingale Health
Teemu Suna
CEO, Founder
p. +358 40 196 1669
press@nightingalehealth.com
Nightingale Health is the Finnish innovator of an internationally recognized NMR (Nuclear Magnetic Resonance) metabolomics technology, supplying biomarker analysis services for human serum, plasma, urine and umbilical cord blood samples. By measuring biomarkers from multiple pathways in a single experiment, Nightingale equips biomedical researchers with comprehensive insights into the effects of lifestyle factors and future disease risk, accelerating breakthroughs in precision medicine. The company is investing and working towards integrating its technology into clinical practice to bring about precision medicine, helping to empower patients to follow their own well-being and take proactive steps to stay healthy.
For more information, please visit www.nightingalehealth.com